First Patient Enrolled in Phase 2 Study of Nugel in AD
Shaperon, Inc. has enrolled the first patient in the Phase 2 clinical trial for Nugel, an atopic dermatitis (AD) candidate. Nugel is a G-protein-coupled receptor 19 (GPCR19) agonist, which suppresses a broad spectrum of inflammatory cytokines including interleukin (IL)-1β, IL-18, IL-6, and tumor necrosis factor (TNF)-α by controlling both priming and activation phase of inflammasome. […]